PL4099986T3 - Preparaty okulistyczne do stosowania miejscowego na bazie ksantanu o zmniejszonym schemacie dawkowania - Google Patents

Preparaty okulistyczne do stosowania miejscowego na bazie ksantanu o zmniejszonym schemacie dawkowania

Info

Publication number
PL4099986T3
PL4099986T3 PL21711634.2T PL21711634T PL4099986T3 PL 4099986 T3 PL4099986 T3 PL 4099986T3 PL 21711634 T PL21711634 T PL 21711634T PL 4099986 T3 PL4099986 T3 PL 4099986T3
Authority
PL
Poland
Prior art keywords
xanthan
dosage regimen
topical formulations
reduced dosage
based ophthalmic
Prior art date
Application number
PL21711634.2T
Other languages
English (en)
Inventor
Maria Grazia Mazzone
Claudine Civiale
Andrea Sudano Roccaro
Elena SOLFATO
Ilenia Abbate
Maria Cristina Curatolo
Original Assignee
Sifi S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sifi S.P.A. filed Critical Sifi S.P.A.
Publication of PL4099986T3 publication Critical patent/PL4099986T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL21711634.2T 2020-02-06 2021-02-05 Preparaty okulistyczne do stosowania miejscowego na bazie ksantanu o zmniejszonym schemacie dawkowania PL4099986T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102020000002296A IT202000002296A1 (it) 2020-02-06 2020-02-06 Formulazioni topiche oftalmiche a base di xantano con ridotta posologia
PCT/IB2021/050951 WO2021156813A2 (en) 2020-02-06 2021-02-05 Xanthan-based ophthalmic topical formulations with a reduced dosage regimen

Publications (1)

Publication Number Publication Date
PL4099986T3 true PL4099986T3 (pl) 2025-10-06

Family

ID=70480548

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21711634.2T PL4099986T3 (pl) 2020-02-06 2021-02-05 Preparaty okulistyczne do stosowania miejscowego na bazie ksantanu o zmniejszonym schemacie dawkowania

Country Status (10)

Country Link
US (1) US20230338540A1 (pl)
EP (1) EP4099986B1 (pl)
CA (1) CA3169401A1 (pl)
ES (1) ES3034195T3 (pl)
HR (1) HRP20250817T1 (pl)
IT (1) IT202000002296A1 (pl)
MX (1) MX2022009533A (pl)
PL (1) PL4099986T3 (pl)
RS (1) RS66989B1 (pl)
WO (1) WO2021156813A2 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12023344B2 (en) * 2022-05-25 2024-07-02 Famygen Life Sciences, Inc. Topical otic, ophthalmic, and nasal corticosteroid formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754712B1 (fr) * 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
ATE528009T1 (de) * 2002-04-30 2011-10-15 Sifi Spa Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten
US20110117189A1 (en) * 2008-07-08 2011-05-19 S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. Ophthalmic compositions for treating pathologies of the posterior segment of the eye
EP2585037A1 (en) * 2010-06-23 2013-05-01 Alcon Research, Ltd. Topical ophthalmic suspensions containing tobramycin and dexamethasone
HRP20241509T1 (hr) * 2011-10-12 2025-01-03 Bausch & Lomb Incorporated Pripravak za oči koji sadrži bromfenak s povećanom bioraspoloživošću
IN2013CH05270A (pl) * 2013-11-15 2015-09-04 Micro Labs Ltd
WO2019166926A2 (en) * 2018-02-27 2019-09-06 Shilpa Medicare Limited Methotrexate ophthalmic solution

Also Published As

Publication number Publication date
IT202000002296A1 (it) 2021-08-06
US20230338540A1 (en) 2023-10-26
EP4099986C0 (en) 2025-06-04
WO2021156813A2 (en) 2021-08-12
RS66989B1 (sr) 2025-07-31
EP4099986A2 (en) 2022-12-14
EP4099986B1 (en) 2025-06-04
ES3034195T3 (en) 2025-08-13
MX2022009533A (es) 2022-09-09
HRP20250817T1 (hr) 2025-09-12
WO2021156813A3 (en) 2021-09-30
CA3169401A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
HK1222340A1 (zh) 抗folr1免疫缀合物给药方案
IL308389A (en) Dosing regimens for acubactadine
PL4099986T3 (pl) Preparaty okulistyczne do stosowania miejscowego na bazie ksantanu o zmniejszonym schemacie dawkowania
PT4340842T (pt) Sotorasib para utilização no tratamento de cancro
GB202011605D0 (en) Topical formulation
IL315178A (en) Dosage regimen
PL4358939T3 (pl) Preparat miejscowy diklofenaku o wysokim stopniu wchłanianiu
GB2596872B (en) Handling injected instructions in a processor
PL3958835T3 (pl) Preparat do stosowania miejscowego
GB202006819D0 (en) Dosage regimen
RS67818B1 (sr) Degradantno jedinjenje u leku
HUE067870T2 (hu) A-vitamin készítmény
EP4267113A4 (en) LEVODOPA DOSING SCHEME
EP4221694A4 (en) GASTRORETENTIVE STRUCTURED DOSAGE FORM
GB202319534D0 (en) Dosage regimen
GB202306662D0 (en) Dosage regimen
IL285425A (en) High-dose therapeutic, non-aqueous curcuminoid solutions
GB202015771D0 (en) Dosage regimen
GB202014116D0 (en) Dosage regimen
GB202318802D0 (en) A topical formulation
GB202218592D0 (en) A topical formulation
GB202006699D0 (en) Dosage regimen
PL4157247T3 (pl) Cysteamina do zastosowania w terapii przeciwwirusowej
GB202301936D0 (en) A dosage calculator
HK40131582A (en) A dosing regimen